DTIL, US74019P2074

Precision BioSciences stock gains 3.00 percent to EUR 5.84

Published on 10/20/2026 at 22:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter consensus revenue is USD 1.38 million for November 2, 2026. DTIL stock costs EUR 5.84 on October 20, 2026, up 3.00 percent versus Stuttgart close.

Price and reporting milestones

Precision BioSciences stock gained 3.00 percent to EUR 5.84 on October 20, 2026.
MarketBeat listed consensus revenue of USD 1.38 million for the third quarter of 2026.
The next estimated earnings date is November 2, 2026.
Precision BioSciences will present PBGENE-HBV data at The Liver Meeting from November 5 to November 9, 2026.

DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences stock (ISIN US74019P2074) was trading at EUR 5.84 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST, up 3.00 percent versus the Stuttgart close of October 20, 2026 at EUR 5.67. The next reporting date is estimated for November 2, 2026, with consensus revenue of USD 1.38 million for the third quarter of 2026, according to MarketBeat.

Revenue expectations stay modest

MarketBeat lists consensus earnings of minus USD 0.85 per share for the third quarter of 2026 alongside the USD 1.38 million revenue estimate. The same source compares that outlook with a loss of USD 1.84 per share and revenue of USD 0.01 million in the year-earlier quarter.

The estimates put the coming report in a results-driven phase for the clinical-stage biotechnology company. Precision BioSciences is developing gene-editing therapies through its ARCUS platform, with programs targeting chronic hepatitis B and Duchenne muscular dystrophy.

The stock's wider range

Nasdaq data put the 52-week range at USD 3.53 to USD 9.62 as of October 20, 2026. The USD 181.1 million market capitalization and the negative price-to-earnings ratio of minus 2.33 reflect a company still investing ahead of commercial product revenue.

Precision BioSciences has also scheduled a clinical presentation. According to Business Wire, the company will deliver a late-breaking oral presentation at The Liver Meeting in Denver from November 5 to November 9, 2026. The presentation is scheduled for November 8, 2026 at 2:15 p.m. MST.

What comes next for DTIL?

The November 2 earnings release should provide the next quantified update on revenue and the quarterly loss. The November clinical presentation adds a separate date for investors tracking PBGENE-HBV development.

Price after the Stuttgart close

Precision BioSciences was trading at EUR 5.84 at Lang & Schwarz on October 20, 2026 at 10:00 p.m. CEST, up 3.00 percent versus the Stuttgart close of October 20, 2026 at EUR 5.67. The further course of trading is shown by the continuously updated real-time quote of Precision BioSciences stock.